Drug
Obinutuzumab clinical trials
Also written GA101, RO5072759, Gazyva and Gazyvaro.
- studies test it
- 213
- open now
- 59
- in phase 3
- 25
- first study started
- 2007
Keep track of what changes. Save the obinutuzumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Studies by the year they started
211 studies that test it; most in 2015 (24); 2 more planned to start later
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 5 |
| 2013 | 5 |
| 2014 | 9 |
| 2015 | 24 |
| 2016 | 16 |
| 2017 | 15 |
| 2018 | 14 |
| 2019 | 13 |
| 2020 | 14 |
| 2021 | 21 |
| 2022 | 12 |
| 2023 | 10 |
| 2024 | 19 |
| 2025 | 13 |
| 2026 | 11 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 65
- Phase 2
- 151
- Phase 3
- 25
- Phase 4
- 1
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 16
Who runs them
Industry 67 · Other 146
Hoffmann-La Roche (35) · M.D. Anderson Cancer Center (12) · Genentech, Inc. (9) · German CLL Study Group (8) · Institute of Hematology & Blood Diseases Hospital, China (8) · National Cancer Institute (NCI) (7) · Memorial Sloan Kettering Cancer Center (6) · Dana-Farber Cancer Institute (4)
Often tested with
Tested in the same studies.
Venetoclax (49) · Ibrutinib (26) · Lenalidomide (25) · Rituximab (18) · Acalabrutinib (16) · Bendamustine (16) · Zanubrutinib (14) · Glofitamab (12)
Studies
Open first, then newest update. How each study uses obinutuzumab is read from its arms, and is right about nine times in ten.
Testing it · 213
- Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHLRecruitingPhase 2New York Medical CollegeNCT02393157Written as Obinutuzumab
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3BeOne MedicinesNCT06943872Written as Obinutuzumab
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3National Cancer Institute (NCI)NCT04269902Written as Obinutuzumab
- Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Not yet recruitingPhase 2Fred Hutchinson Cancer CenterNCT07887061Written as Obinutuzumab
- Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT06649812Written as Obinutuzumab
- Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell LymphomaRecruitingPhase 1/2National Cancer Institute (NCI)NCT03223610Written as Obinutuzumab
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric ParticipantsRecruitingPhase 2Hoffmann-La RocheNCT05039619Written as Obinutuzumab
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2Mayo ClinicNCT03516617Written as Obinutuzumab
- Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLLNot yet recruitingPhase 1/2Dana-Farber Cancer InstituteNCT07847957Written as Obinutuzumab
- Obinutuzumab in Systemic SclerosisNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07842523Written as Obinutuzumab
- Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial ResponseRecruitingPhase 2Providence Health & ServicesNCT06175000Written as Obinutuzumab
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07799220Written as Obinutuzumab
- Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT04169737Written as Obinutuzumab
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)RecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06561360Written as Obinutuzumab
- Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06108232Written as Obinutuzumab
- A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to RituximabRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07268521Written as Obinutuzumab
- A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)Not yet recruitingPhase 3Zhao MinghuiNCT07767188Written as obinutuzumab (RO5072759)
- A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)RecruitingPhase 2Medical University InnsbruckNCT07710157Written as Obinutuzumab Injection
- Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).RecruitingPhase 2M.D. Anderson Cancer CenterNCT06967610Written as Obinutuzumab
- Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II TrialNot yet recruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT07721363Written as Obinutuzumab
See all 213 studies that test obinutuzumab →
Given in every arm · 82 — obinutuzumab is usual care beside what is tested
- Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) in Relapsed or Refractory Primary and Secondary Central Nervous System LymphomaNot yet recruitingPhase 2The First Affiliated Hospital with Nanjing Medical UniversityNCT07888621Written as Obinutuzumab
- Study of NX-5948 in Combination With Other Agents in Adults With B-cell MalignanciesRecruitingPhase 1/2Nurix Therapeutics, Inc.NCT07520006Written as obinutuzumab
- GLORY: Glofit-GemOx With Liso-Cel For LymphomaRecruitingPhase 2Massachusetts General HospitalNCT07711483Written as Obinutuzumab
- Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's TransformationRecruitingPhase 2Christine RyanNCT06043674Written as Obinutuzumab
- Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell LymphomasRecruitingPhase 2National Research Center for Hematology, RussiaNCT07883135Written as Obinutuzumab
- Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHLRecruitingPhase 2Hoffmann-La RocheNCT06806033Written as Obinutuzumab
- A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell LymphomaRecruitingPhase 3Hoffmann-La RocheNCT06084936Written as Obinutuzumab
- A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin LymphomaRecruitingPhase 1/2Hoffmann-La RocheNCT05533775Written as Obinutuzumab
- Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 2University of California, San FranciscoNCT06252675Written as Obinutuzumab
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06213311Written as Obinutuzumab
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Obinutuzumab
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell TherapyRecruitingPhase 2National Cancer Institute (NCI)NCT07003295Written as Obinutuzumab
- TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingPhase 2Brown UniversityNCT07502872Written as Obinutuzumab
- A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLLRecruitingPhase 3German CLL Study GroupNCT05197192Written as Obinutuzumab
- Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit LymphomaNot yet recruitingPhase 2/3National Cancer Institute (NCI)NCT07724457Written as Obinutuzumab
- Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingPhase 2The First Affiliated Hospital of Soochow UniversityNCT07774234Written as Obinutuzumab
- Phase I/II Open-label Study Evaluating The Safety And Efficacy of Concomitant Administration of Anti-CD19 CAR T-cell Therapy and Lenalidomide in Refractory/Relapsed Chronic Lymphocytic Leukemia Patients.RecruitingPhase 1/2Vitebsk Regional Clinical Cancer CentreNCT06762431Written as Obinutuzumab Injection [Gazyva]
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingPhase 2Massachusetts General HospitalNCT06849713Written as Obinutuzumab
- A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular LymphomaNot yet recruitingPhase 3Ruijin HospitalNCT07719855Written as obinutuzumab
- A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06765317Written as Obinutuzumab:
Showing 20 of 82.
As the comparator · 7 — what is tested is compared with obinutuzumab
- Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapyRecruitingPhase 2University of BirminghamNCT05848765Written as Obinutuzumab
- Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingPhase 3BeOne MedicinesNCT06073821Written as Obinutuzumab
- A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingPhase 3Janssen Research & Development, LLCNCT03462719Written as Obinutuzumab
- Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5Active, not recruitingPhase 3The Lymphoma Academic Research OrganisationNCT06284122Written as Obinutuzumab
- A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) InhibitorsActive, not recruitingPhase 3BeOne MedicinesNCT06970743Written as Obinutuzumab
- Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic LeukemiaTerminatedPhase 3TG Therapeutics, Inc.NCT02612311Written as Obinutuzumab
- A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnPhase 1Hoffmann-La RocheNCT03369964Written as Obinutuzumab
Codes
What other systems call obinutuzumab · ClinicalTrials.gg INT005485
- MeSH (NLM) C543332obinutuzumabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) O43472U9X8OBINUTUZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 974779Confirmed FDA, Wikidata
- Wikidata Q389496obinutuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C70741ObinutuzumabOne source FDA
- DrugBank DB08935One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C543332 | obinutuzumab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | O43472U9X8 | OBINUTUZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 974779 | — | Confirmed FDA, Wikidata |
| Wikidata | Q389496 | obinutuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C70741 | Obinutuzumab | One source FDA |
| DrugBank | DB08935 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.